Drugs / epigallocatechin-3-gallate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06265532 Comparator | Feb 2024 → Jan 2026 | idiopathic pulmonary fibrosis | Hal Chapman | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epigallocatechin-3-gallate | “Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, pharmacokinetic...” NCT06265532 ↗ |
| Known as | EGCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06265532 ↗ |
| Modality | Other / unclassified | “Dietary Supplement: EGCG Capsules” NCT06265532 ↗ |
| Route | Oral | “taken orally daily for 12 weeks.” NCT06265532 ↗ |